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Activating mutations of MPL exon 10
have been described in a minority of
patients with idiopathic myelofibrosis
(IMF) or essential thrombocythemia (ET),
but their prevalence and clinical signifi-
cance are unclear. Here we demonstrate
that MPL mutations outside exon 10 are
uncommon in platelet cDNA and identify
4 different exon 10 mutations in granulo-
cyte DNA from a retrospective cohort of
200 patients with ET or IMF. Allele-
specific polymerase chain reaction was
then used to genotype 776 samples
from patients with ET entered into the
PT-1 studies. MPL mutations were iden-
tified in 8.5% of JAK2 V617F patients
and a single V617F patient. Patients
carrying the W515K allele had a signifi-
cantly higher allele burden than did
those with the W515L allele, suggesting
a functional difference between the
2 variants. Compared with V617F ET
patients, those with MPL mutations dis-
played lower hemoglobin and higher
platelet levels at diagnosis, higher se-
rum erythropoietin levels, endogenous
megakaryocytic but not erythroid colony
growth, and reduced bone marrow ery-
throid and overall cellularity. Compared
with V617F patients, those with MPL
mutations were older with reduced bone
marrow cellularity but could not be iden-
tified as a discrete clinicopathologic
subgroup. MPL mutations lacked prog-
nostic significance with respect to
thrombosis, major hemorrhage, myelofi-
brotic transformation or survival. (Blood.
2008;112:141-149)
Introduction
The myeloproliferative disorders, comprising essential thrombocy-
themia (ET), polycythemia vera (PV) and idiopathic myelofibrosis
(IMF), are hematopoietic stem cell disorders characterized by the
overproduction of one or more mature myeloid lineages. Although
the clonal nature of these disorders was recognized some 3 decades
ago,1 their molecular basis remained obscure until the identification
of the activating JAK2 V617F mutation.2-5 The vast majority of
patients with PV harbor a mutation in JAK2, with JAK2 V617F
seen in around 97%3 and mutations in JAK2 exon 12 found in many
of the remainder.6-8 PV patients with JAK2 exon 12 mutations differ
from those with JAK2 V617F, presenting at a younger age with
higher hemoglobin levels, lower platelet counts, and lower white
cell counts at diagnosis.6 The JAK2 V617F mutation is present in
around half of patients with ET and is associated with features
resembling a “forme-fruste” of PV, including increased erythropoi-
esis, increased granulopoiesis, and increased rates of venous
thrombosis compared with the JAK2 V617F group.9-12 The JAK2
V617F mutation is also present in around half of patients with IMF,
and is associated with higher neutrophil and platelet counts at
diagnosis, reduced likelihood of transfusion dependence, and
probably a poorer survival compared with the JAK2 V617F
group.13-15
Mutations in the juxtamembrane region of the thrombopoi-
etin receptor MPL have recently been described in IMF and as a
rare occurrence in ET.16,17 Biochemical and cell line studies
indicate an autoinhibitory role for this region, with disruption
leading to receptor activation in the absence of thrombopoietin
binding.18 Expression of the MPL W515L allele resulted in
cytokine-independent growth of 32D, UT7, and BaF3 cell lines,
together with constitutive phosphorylation of JAK2, STAT3,
STAT5, AKT and ERK.16 Transplantation of mice with bone
marrow expressing the MPL W515L allele resulted in a myelo-
proliferative disorder (MPD)–like disease characterized by
marked thrombocytosis, splenomegaly, splenic infarction, and
reduced life expectancy.16 MPL mutations in IMF patients have
been associated with lower hemoglobin levels at diagnosis and
increased risk of transfusion dependence compared with both
JAK2 V617F and JAK2 V617F patients.19 Mutations in MPL
have been reported in a small minority of patients with ET17 but
their clinical significance remains unclear. Here we describe the
prevalence of MPL mutations in a retrospective cohort of
unselected patients with ET or IMF, and also report the clinical
and laboratory features associated with MPL mutations in the
large prospective Primary Thrombocythaemia 1 (PT-1) cohort.
Submitted December 29, 2007; accepted April 6, 2008. Prepublished online as
Blood First Edition paper, May 1, 2008; DOI 10.1182/blood-2008-01-131664.
The online version of this article contains a data supplement.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked ‘‘advertisement’’ in accordance with 18 USC section 1734.
© 2008 by The American Society of Hematology
141BLOOD, 1 JULY 2008  VOLUME 112, NUMBER 1
For personal use only.on January 9, 2017. by guest  www.bloodjournal.orgFrom 
Methods
Retrospective cohort: patients and samples
Patients aged 18 years or over, who met the Polycythaemia Vera Study
Group (PVSG) criteria for either ET or IMF20 were recruited from MPD
clinics in Cambridge, London, Sheffield, Birmingham, and Odense.
Institutional and multiregion Ethics Committee approval was obtained
and the study was carried out in accordance with the principals of the
Declaration of Helsinki.
Granulocytes were prepared by centrifugation of whole blood
through a Ficoll density gradient, and T cells were isolated from the
mononuclear cell layer by anti-CD2 magnetic beads (DynaBeads;
Invitrogen, Paisley, United Kingdom). Mean purity was greater than
95% for granulocytes and 91% for T cells. Platelets were isolated from
whole blood by 3 rounds of centrifugation at 150g for 20 minutes at
room temperature, followed by negative selection of CD45 cells using
magnetic beads (DynaBeads, Invitrogen). RNA was prepared from TRI
reagent (Sigma-Aldrich, Gillingham, United Kingdom) as per the
manufacturer’s instructions. cDNA was synthesised using M-MLV
(Invitrogen) as per the manufacturer’s instructions.
PT-1 study: patients and samples
Newly diagnosed and previously treated patients, aged 18 years or over,
who met the Polycythaemia Vera Study Group (PVSG) criteria for ET,20
were recruited into one of 3 multicenter PT-1 studies: the Medical Research
Council high-risk trial, in which high-risk patients were randomly assigned
to either hydroxyurea plus aspirin or to anagrelide plus aspirin21; the
National Cancer Research Institute intermediate-risk study, a randomiza-
tion between aspirin alone or hydroxyurea plus aspirin; or the National
Cancer Research Institute low-risk study, a prospective observational study
of low-risk patients given aspirin alone. Patients entered a higher risk study
if they developed appropriate features. The study protocol was approved by
institutional ethics committees in all participating centers, and written
informed consent was obtained in accordance with the Declaration of
Helsinki from all patients. This study is registered at http://isrctn.org as
#72251782 and at http://eudract.emea.europa.eu/ as #2004-000245-38.
Further information regarding the trial can be accessed at
http://www.ctsu.ox.ac.uk/projects/leuk/pt1.
Details obtained at trial entry included diagnostic features such as blood
counts, cytogenetics, and clinical complications at or preceding diagnosis.
Follow-up forms were completed every year by the patient’s clinician,
documenting medications, blood counts, and clinical events for which
standard definitions were used.21 All data were collected prospectively with
more than 99% of patients having complete follow-up. The median
follow-up in this study was 36.5 months. Bone marrow trephines were
independently reviewed by 3 hematopathologists who were aware of the
patient’s age and sex but unaware of JAK2 and MPL status, and scored for
reticulin grade on a 0 to 4 scale, cellularity, megakaryocyte clustering, and
atypical megakaryocyte nuclear morphology.22 Where there was disagree-
ment, the mean reticulin score and the mode of other scores were used.
Samples of peripheral blood were requested at trial entry from all
patients, and 776 samples were received from the 1022 patients entered.
Whole-blood genomic DNA was extracted commercially (Whatman
International, Ely, United Kingdom) and used for genotyping and
mutant allele quantitation.
Mutation detection
JAK2 V617F mutation status was determined by allele-specific polymerase
chain reaction (PCR) as previously described.3 MPL exon 10 screening was
performed by direct sequencing of PCR products from peripheral blood
granulocytes. Allele-specific PCR assays were developed for the MPL
W515L, MPL W515K and MPL S505N alleles, and the sensitivity of each
assay was established by mixing experiments using normal and mutant
genomic DNA.
Mutant allele quantitation
Pyrosequencing assays were established for each MPL-mutant allele to
quantitate mutant allele burden. Mixing experiments using cloned PCR
products were performed for each assay, and the results used to plot a
dilution curve from which the mutant allele burden was read (Figure S1,
available on the Blood website; see the Supplemental Materials link at the
top of the online article). For the MPL S505N and MPL W515L alleles,
the dilution curve was plotted against the allele proportion generated by the
pyrosequencing software. As the software is unable to quantitate allele
proportion where 2 or more adjacent bases are changed, MPL W515Ki and
MPL W515Kii alleles were quantitated using the following formulas:
MPL W515Ki  (A/2)/([A/2]  T)
and MPL W515Kii  (A/3)/([A/3]  T)
where A and T are the pyrosequencing peak heights for the mutant
and wild-type bases, respectively (Figure S1).
Statistical analysis
Due to the large number of hypothesis tests performed in the paper, we
elected to use a threshold of P less than .01 to define statistical significance,
thus reducing the risk of false positive results. Pairwise univariate analyses
comparing diagnostic variables between the MPL-mutant and either JAK2
V617F or JAK2 V617F groups were performed using the t test for
continuous variables, Fisher exact test for 2  2 tables, and Cochran-
Armitage test for trend with exact P values for ordinal variables. Multivari-
ate analyses for the associations of ordinal variables with mutation status,
accounting for the effects of age, were performed using proportional odds
logistic regression. Complication rates during follow-up were assessed
using Kaplan-Meier life tables and log-rank analyses. Confidence intervals
for odds ratios (OR) of complications in the year prior to diagnosis were
calculated using the asymptotic formula 1/a  1/b  1/c  1/d to estimate
the variance of the log(OR). Mulitvariate survival analyses were performed
using Cox proportional hazards models. S-plus v 7.0 (Insightful, Seattle,
WA) was used for all statistical analyses, apart from the exact methods, for
which SAS v9.0 (SAS, Cary, NC) was used.
Colony analysis
For erythroid colony analysis, mononuclear cells were plated at 105
cells/mL in Methocult (H4531; StemCell Technologies, Vancouver, BC) in
the presence or absence of erythropoietin (2 U/mL). For megakaryocyte
colony analysis, mononuclear cells were plated at 3  105/mL in Megacult
(StemCell Technologies) in the presence or absence of cytokines (thrombo-
poietin 50 ng/mL, IL-3 10 ng/mL and IL-11 50 ng/mL). Cultures were
incubated for 14 days at 37°C, high humidity, and 5% CO2. Individual
erythroid colonies were placed in water and heated to 95°C for 8 minutes
for DNA preparation. Single colonies were genotyped for the MPL W515L
mutation by either pyrosequencing or direct sequencing. Colonies were
classified as heterozygous if equal amounts of wild-type and mutant alleles
were seen, and as wild-type or homozygous if only the wild-type or mutant
allele was present, respectively. Whole megakaryocyte cultures were
dehydrated and stained for GpIIb/IIIa expression following the manufactur-
er’s instructions (StemCell Technologies).
Results
MPL mutations outside exon 10 are uncommon in ET patients
negative for the JAK2 V617F mutation
To investigate the possibility that JAK2 V617F patients might
harbor MPL mutations other than those previously described,16,17
we sequenced the entire MPL coding region in 18 patients with ET
and 2 patients with IMF. As previous studies have indicated that
JAK2 V617F ET patients have a more isolated megakaryocyte
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proliferation,9 platelet-derived cDNA was used for mutation screen-
ing. One patient with ET carried a mutation in MPL exon 10 (MPL
W515L); all other base changes seen were previously reported
single nucleotide polymorphisms (data not shown). These results
indicate that mutations outside MPL exon 10 are not common in
V617F ET patients, although our data do not exclude the existence
of such mutations in a small minority of patients. To identify
different types of mutations within exon 10, we proceeded to
sequence MPL exon 10 in granulocyte DNA from 200 patients. Of
these, 88 had ET (47 V617F and 41 V617F) and 112 had IMF
(57 V617F and 55 V617F). Mutations were identified in
11 patients. Two carried MPL S505N mutations (1 ET and 1 IMF),
7 carried MPL W515L mutations (2 ET and 5 IMF) and 2 carried
MPL W515K mutations (both IMF; 1 W515Ki and 1 W515Kii). In
this cohort, the prevalence of MPL mutations was 3.4% in ET and
7.1% in IMF. None of the MPL-mutant patients in this cohort had a
coexisting JAK2 V617F mutation. Two different mutations result-
ing in the same MPL W515K amino acid substitution were
observed (MPL W515Ki and MPL W515Kii, respectively, Figure
1A). The MPL S505N mutation has been described as an inherited
mutation in a Japanese pedigree with familial thrombocythemia.23
However, in our ET patient, the majority of T cells (Figure 1A) and
buccal cells (data not shown) did not carry the mutation, strongly
suggesting that it was acquired in this individual.
Development of assays for the detection and quantitation of
MPL exon 10 mutations
To investigate the clinical significance of MPL exon 10 mutations
in patients with ET, we wished to assess the prevalence of these
mutations in samples from patients entered into the PT-1 studies,
for whom comprehensive diagnostic and prospectively acquired
follow-up data are available. However, these samples were from
unfractionated whole blood. Because JAK2 or MPL mutations are
absent from or found at a low level in lymphocytes, and because a
variable proportion of the granulocytes were also likely to be
normal, it was important to develop sensitive assays for each
mutant MPL allele. We therefore developed 3 separate allele-
specific PCR assays to detect the MPL S505N, MPL W515L and
MPL W515K alleles, with the W515K assay being able to detect
both the W515Ki and W515Kii mutations (Figure 1B). To assess the
sensitivity of the allele-specific PCR assays, we quantitated mutant
allele burden in patient samples by pyrosequencing (see “Mutant
allele quantitation” and Figure S1). Allele-specific PCR was then
performed on dilutions corresponding to 1% to 9% mutant allele
burden. As shown in Figure 1C, the assays for MPL S505N and
MPL W515L could detect a mutant allele burden of approximately
1%, whereas the assay for MPL W515Ki and MPL W515Kii could
detect a mutant allele burden of approximately 3% to 5%.
Clinical and laboratory features of MPL mutations in ET
Patients in the PT-1 cohort (n  776) were genotyped for the MPL
S505N, MPL W515L and MPL W515K mutations using allele-
specific PCR. MPL mutations were detected in 32 patients, account-
ing for 4.1% of all ET patients (95% confidence interval [CI]
2.9%-5.8%, Table 1) and 8.5% of JAK2 V617F ET patients. MPL
W515L was the most common mutation, seen in 24 patients;
5 patients had MPL W515K (all MPL W515Ki allele) and 3 patients
had MPL S505N mutations. In all patients with MPL W515K or
MPL S505N alleles, the presence of the mutation was confirmed by
both direct sequencing and pyrosequencing. Of the 24 MPL W515L
mutations, 19 were detected by both direct sequencing and
pyrosequencing, 3 were detected by pyrosequencing but not direct
sequencing, and 2 were detected by allele-specific PCR alone. In
these 2 patients, the presence of the mutation was confirmed by
repeating the allele-specific PCR using an independent blood
sample. Of the 32 MPL-mutant patients, one also carried the JAK2
V617F mutation, and is included in the MPL-mutant group in the
statistical analysis. No patient was positive for more than one
MPL-mutant allele.
Laboratory and clinical features of the MPL-mutant group were
compared with both the JAK2 V617F and JAK2 V617F groups,
both of which lack MPL mutations. As shown in Table 1,
MPL-mutant patients were significantly older at diagnosis than
JAK2 V617F patients (mean vs mean; P  .001). Compared with
JAK2 V617F patients, MPL-mutant patients had lower hemoglo-
bin and higher platelet levels at diagnosis (mean vs mean; P  .001
and mean vs mean; P  .006, respectively). There were no
differences, however, in diagnostic blood counts between the
MPL-mutant and JAK2 V617F groups. There were also no
significant differences in the presence of splenomegaly or bone
marrow cytogenetic abnormalities between the groups.
Figure 1. Detection of MPL exon 10 mutations. (A) Sequence traces of the 4 MPL
exon 10 mutant alleles, showing 2 different mutations leading to the same MPL
W515K substitution (MPL W515Ki and MPL W515Kii), and MPL S505N as an
acquired mutation. (B) Allele-specific PCR strategy showing the common forward and
reverse intronic primers and the allele-specific primer within MPL exon 10. (C) Mixing
experiments with normal and mutant DNA demonstrating the sensitivity of the
allele-specific PCR assays used for mutation screening. The images were captured
on a Gel Doc 200 imager (Bio-Rad, Hercules, CA) using Quantity One software
(Bio-Rad). NA indicates T cell sample not available from this patient; Pt, patient
sample; WT, wild-type; NTC, no template control.
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Bone-marrow trephine biopsies at diagnosis were available
from 311 patients, including 13 patients with MPL mutations,
comprising 2 S505N, 2 W515K, and 9 W515L patients. These were
assessed independently by 3 hematopathologists who were aware
of the patients’ age and sex but unaware of JAK2 or MPL mutation
status (Table 2). Given the known association between age and
bone marrow cellularity, we included patient age as a variable in
the statistical analyses for cellularity. There were no differences in
the mean reticulin grade, megakaryocyte cellularity, or the pres-
ence of megakaryocyte clusters and atypia between the MPL-
mutant, JAK2 V617F and JAK2 V617F groups. However,
trephine biopsies from the MPL-mutant group were less cellular
than both the JAK2 V617F and JAK2 V617F groups (P  .001
[ .001 with age] and P  .005 [.003 with age], respectively).
Compared with the JAK2 V617F group, both erythroid and
granulocytic cellularity were reduced in the MPL-mutant group
(P  .001 [ .001with age] and P  .009 [.02 with age], respec-
tively). Compared with the JAK2 V617F group, the MPL mutant
group showed reduced erythroid cellularity (P  .005 [.004 with
age]). Thus MPL-mutant patients exhibited a more isolated
megakaryocytic proliferation at diagnosis, with a reduction in
overall cellularity compared with both the JAK2 V617F and JAK2
V617F groups. There was, however, considerable overlap be-
tween the histologic appearances observed in the 3 groups of
patients, and our data indicate that MPL mutations as a whole do
not define a distinct histologic subtype of ET. It remains formally
possible that specific MPL mutations are associated with particular
histologic features, but the number of patients with each individual
MPL mutation was too small to address this issue.
Serum erythropoietin levels at trial entry in MPL mutation
patients were significantly higher than JAK2 V617F but not JAK2
V617F patients (mean vs mean; P   .001 and P  .6, respec-
tively). There were no significant differences in iron status between
MPL-mutant patients and both comparator groups, as assessed by
serum ferritin and erythrocyte mean cellular volume (Table 2).
Cytokine-independent colony formation is one of the hallmark
features of the myeloproliferative disorders, with the presence of
both endogenous megakaryocyte and erythroid colonies reported in
patients carrying the JAK2 V617F mutation.3,24 To investigate the
association of MPL mutations and cytokine-independent colony
formation, colony assays were performed using peripheral blood
from 2 hydroxyurea-treated ET patients, and an IMF patient
receiving transfusion support only, all of whom carried the MPL
W515L mutation, and all of whom had only heterozygous and
Table 1. Laboratory and clinical features at diagnosis of 776 ET patients enrolled in the MRC PT1-studies
MPL negative
MPL mutant V617F V617F P (vs V617F) P (vs V617F)
Number 32* 411 333
Percentage (95% CI)
4.1%
(2.9-5.8)
53.0%
(49.4-56.5)
42.9%
(39.4-46.5)
Risk category, no.
Low risk† 0 26 31 .2 .09
Intermediate risk‡ 4 68 46 .8 1.0
High risk§ 28 339 273 .6 .6
Hydroxyurea plus aspirin 13 168 139 .9 .8
Anagrelide plus aspirin 15 171 134
Demographics
Female, no. (%) 17 (53%) 255 (62%) 192 (58%) .3 .7
Male, no. (%) 15 (47%) 156 (38%) 141 (42%)
Median age, y (10th-90th centile) 67 (48-77) 60 (39-77) 52 (32-74) .09  .001
Median disease duration¶, mo. (10th-90th centile) 18 (0-956) 38 (0-1106) 57 (0-2699) .2 .7
Laboratory and clinical features at diagnosis
Hemoglobin (g/L)
Mean plus or minus SD 133  12 145  14 135  14 .001 .3
Median 136 145 136
(10th-90th centile) (119-147) (128-163) (117-153)
White cells (109/L)
Mean plus or minus SD 9.9  2.4 10.6  3.4 9.3  2.7 .2 .2
Median 9.7 10.0 8.8
(10th-90th centile) (7.0-13.3) (7.0-14.6) (6.2-12.8)
Neutrophils (109/L)
Mean plus or minus SD 6.7  2.1 7.4  3.0 6.2  2.2 .3 .2
Median 6.9 6.8 5.8
(10th-90th centile) (4.4-9.6) (4.2-11.0) (3.8-9.1)
Platelet count (109/L)
Mean plus or minus SD 1040  272 900  274 1032  350 .006 .9
Median 962 840 963
(10th-90th centile) (752-1505) (632-1221) (666-1550)
Splenomegaly, no. (%) 0/27 (0%) 11/326 (3%) 11/262 (4%) .7 .6
Abnormal cytogenetics, no. (%) 2/24 (8%) 14/312 (4%) 10/262 (4%) .3 .2
*One patient had both JAK2 V617F and MPL W515L mutations, and is included in the MPL-mutant column.
†Includes 4 patients who subsequently enrolled in the intermediate-risk arm, and 10 in the high-risk arm.
‡Includes 4 patients who were previously enrolled in the low-risk arm and 25 who subsequently enrolled in the high-risk arm.
§Includes 10 and 25 who were previously enrolled in the low- and intermediate-risk arms, respectively.
¶Refers to time elapsed between diagnosis and trial entry.
Comprises patient with MPL S505N and karyotype 45,XY,add(6)(q?15),-7 6, 46,XY 25 and patient with MPL W515L and karyotype 47,XY,14 4, 46,XY 16, both at
diagnosis.
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wild-type erythroid colonies. These investigations demonstrated
the presence of thrombopoietin-independent megakaryocyte colony
growth in all 3 patients studied. In contrast to the JAK2 V617F
mutation, however, we did not observe endogenous erythroid
colonies in any of 5 patients with the MPL W515L mutation (4 ET,
1 IMF). These data confirm previous studies in IMF and extend
these findings to patients with ET.25,26
Clinical outcome of patients with MPL mutations
As part of the PT-1 studies, comprehensive clinical and outcome
data were collected prospectively. Clinical events were indepen-
dently adjudicated according to predefined criteria by a panel of
experts blinded to treatment allocation.21 The median follow-up
was 36.5 months, although the relatively small numbers of patients
in the MPL-mutant cohort meant that only a few end-point events
were recorded in this group. There were no significant differences
between the 3 comparator groups in rates of arterial thrombosis
either before or after trial entry (Table 3); compared with JAK2
V617F patients, MPL-mutant patients had a higher rate of venous
thrombosis after trial entry (odds ratio 34.3, 95% CI: 1.6-725,
P  .02). In view of the large number of hypothesis tests per-
formed, we elected to use a threshold for statistical significance of
P less than or equal to .01. Moreover, the association appeared
weaker in multivariate analysis including patient age, sex, and past
history of venous thrombosis (hazard ratio [HR], 4.7; 95% CI,
0.7-29.5; P  .09), and there was no increased rate of venous
thrombosis in the year before diagnosis. MPL-mutant patients had
an increased rate of death compared with the JAK2 V617F group
on univariate analysis, but this was due to the significantly older
age of the MPL-mutant patients (HR, 1.2; 95% CI, 0.5-3.5 after
correction for patient age; P  .7).
Biologic aspects of MPL mutations
To investigate possible differences between the MPL W515L and
MPL W515K alleles, mutant allele burden was quantitated by
pyrosequencing using whole blood obtained at PT-1 trial entry.
Patients with MPL W515K had a significantly higher mutant allele
burden than those with MPL W515L; the number of patients with a
mutant allele burden more than 50% was 0 of 24 for W515L and
4 of 5 for W515K (P  .001, Figure 2A). There were no significant
differences in age at diagnosis (P  .6), disease duration (P  .5),
use of cytoreductive therapy (P  .2) or proportion of peripheral
blood neutrophils at time of sampling (W515L, 0.67  0.11;
W515K, 0.75  0.05; P  .2) to account for this difference. To
examine the phenotypic correlates of the higher MPL W515K
mutant allele burden, blood counts at diagnosis were compared
between MPL W515L and MPL W515K patients in the PT-1 cohort.
Despite the higher mutant allele burden in the MPL W515K group,
there were no significant differences in diagnostic hemoglobin level
(W515L, 132 11g/L; W515K, 135 16g/L; P .7), neutrophil count
(W515L, 6.5 2.0 109/L; W515K, 8.7 2.7 109/L; P .07)
or platelet count (W515L, 1010 242 109/L; W515K,
Table 2. Bone marrow trephine histology, erythropoietin levels and iron stores in patients enrolled in the MRC PT-1 studies
MPL mutant
MPL negative
P (vs V617F) P (vs V617F)V617F V617F
Bone marrow trephine histology, no.* 13 168 130
Reticulin grade, mean plus or minus SD 1.8  1.0 1.8  0.8 1.9  0.9 .9 .6
Megakaryocyte clusters and nuclear
morphology, no.†
Clusters (absent/loose/tight) 1 / 6 / 6 22 / 99 / 47 12 / 67 / 51 .3 .8
Pyknotic (absent/pres/predom) 6 / 6 / 1 55 / 112 / 1 48 / 79 / 3 .8 .9
Staghorn (absent/pres/predom) 2 / 10 / 1 31 / 132 / 5 23 / 102 / 5 .7 .7
Cloud-like (absent/pres/predom) 5 / 8 / 0 46 / 118 / 4 44 / 85 / 1 .4 .8
Dysplastic (absent/pres/predom) 4 / 8 / 1 57 / 110 / 1 48 / 80 / 2 .6 .6
Cellularity, no.‡
Overall (dec/normal/inc) 3 / 5 / 5 1 / 36 / 131 2 / 43 / 85  .001 .005
Erythroid (dec/ normal/inc) 3 / 9 / 1 5 / 90 / 73 6 / 77 / 47  .001 .005
Granulocytic (dec/normal/inc) 3 / 6 / 4 3 / 74 / 91 2 / 76 / 52 .009 .07
Megakaryocytic (//) 3 / 9 / 1 32 / 88 / 47 25 / 58 / 47 .3 .2
Erythropoietin levels and iron stores
Erythropoietin, U/L§
Mean plus or minus SD 20.7  16.2 9.8  10.8 23.8  28.9 .001 .6
Median 17.4 6.9 14.9
(10th-90th centile) (6.3-33.8) (3.2-17.3) (7.9-42.7)
Mean cell volume, fL¶
Mean plus or minus SD 89.6  5.5 87.6  6.4 89.4  6.1 .08 .8
Median 89.5 88.3 89.4
(10th-90th centile) (83.1-96.9) (79.8-94.2) (83.5-95.2)
Mean cell volume, no. less than 80 fL (%)‡ 2/32 (6.3%) 41/391 (10.5%) 4/312 (1.3%) .4 .2
Ferritin, 	g/L
Mean plus or minus SD 94  79 90  91 90.7  90 .8 .9
Median 54 58 91
(10th-90th centile) (19-213) (23-192) (29-201)
*All bone marrow trephine biopsies were obtained at diagnosis.
†pres indicates present; and predom, predominant.
‡Dec, decreased; inc, increased;,,, increasing cellularity.
§Based on 707 serum samples from trial entry. Normal range for serum erythropoietin, 5 to 25 U/L.
¶Normal range for mean cell volume, 80 to 100 fL.
Based on serum samples taken within 3 months of diagnosis (n  182). Normal range for ferritin, 20 to 300 	g/L.
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1124 397 109/L; P .4). Moreover, there were no significant
differences in blood counts at trial entry (data not shown).
Although none of 24 patients in the PT-1 cohort carrying the
MPL W515L mutation had a mutant allele burden of greater than
50% at trial entry, this does not exclude the presence of a subclone
homozygous for the mutation.27 We therefore genotyped 354 single
erythroid colonies cultured from 4 hydroxyurea–treated ET pa-
tients with MPL W515L mutations (Figure 2B). In 1 of the
4 patients, a single homozygous colony was found of 94 colonies
analyzed; the other 3 patients had only heterozygous colonies, with
or without wild-type colonies. Taken together with the mutant
allele quantitation, our data suggest that ET patients carrying the
MPL W515K allele commonly harbor clones in which the ratio of
wild-type to mutant alleles is reduced (for example, as a result of
mitotic recombination or deletion of the wild-type allele), but that
such clones are less common in patients with the MPL W515L
allele. Of the 5 IMF patients with W515L mutations, 3 showed
predominance of the mutant allele by direct sequencing (data not
shown), indicating that subclones with reduced or lost wild-type
allele can occur with this mutation, and may be associated with the
development of myelofibrosis.
Three patients in the PT-1 cohort harbored an MPL S505N
mutation, with mutant allele burdens of 62%, 47%, and 17%.
Further samples were available from 1 patient (mutant allele
burden 17%) which demonstrated the absence of the mutation in
buccal cells (data not shown), and the presence of both wild-type
and heterozygous erythroid colonies (Figure 2B), indicative of an
acquired mutation.
Discussion
In this paper we report the existence of 4 mutant MPL alleles in
patients with a JAK2 V617F MPD. No mutations were detected
outside exon 10 despite the analysis of platelet cDNA, which
excludes the possibility that such mutations might be restricted to
the megakaryocyte lineage. Our results are consistent with and
extend 2 previous studies using genomic DNA from 14 adults with
Table 3. Thrombotic, hemorrhagic and transformation events after trial entry and in the year before diagnosis
MPL
mutant
MPL OR versus V617F
(95% CI)
OR versus V617F
(95% CI)
P*
(vs V617F)
P*
(vs V617F)V617F V617F
Number 32 411 333
Arterial thrombosis
In year before diagnosis† 4 38 20 1.4 (0.5-4.2) 2.2 (0.7-7.0) .5 .2
Myocardial infarction 0 6 5
Stroke 1 10 4
Transient ischemic attack 3 23 13
After trial entry† 2 25 19 1.0 (0.2-4.3) 1.1 (0.2-5.2) .9 .9
Myocardial infarction 1 7 6
Unstable angina 0 5 1
Stroke 1 7 7
Transient ischemic attack 1 5 6
Other‡ 0 2 1
Venous thromboembolism
In year before diagnosis† 1 10 2 1.3 (0.2-10.4) 5.3 (0.5-60.6) .6 .2
Deep vein thrombosis 0 3 1
Pulmonary embolism 0 3 1
Splanchnic vein thrombosis 0 2 0
Retinal vein thrombosis 1 2 1
Cerebral sinus thrombosis 0 1 0
After trial entry† 2 11 3 2.6 (0.4-19.3) 34.3 (1.6-725) .3 .02 (.09)§
Deep vein thrombosis 2 5 3
Pulmonary embolism 0 5 0
Splanchnic vein thrombosis 0 2 0
Major hemorrhage
After trial entry† 2 18 12 1.3 (0.3-6.8) 1.9 (0.3-12.1) .7 .5
Gastrointestinal 2 6 6
Intracranial 0 3 4
Epistaxis 0 5 0
Other¶ 0 4 2
Death 5 34 18 1.8 (0.6-5.5) 4.5 (1.1-18.4) .3 .04 (.07)
Hematologic transformation
Myelofibrosis# 2 7 11 6.2 (0.6-66.6) 2.5 (0.3-17.7) .1 .4
Acute leukemia/MDS 0 5 2 0.3 (0.02-7.2) 0.3 (0.01-47.0) .5 .7
Polycythemia vera 0 6 0 0.3 (0.02-6.5) NA .5 NA
Data are numbers, with 95% CI where indicated.
*Assessed by Pearson chi-square test with Yates continuity correction for events preceding diagnosis and log-rank test for events after trial entry.
†Indicates total patients rather than total events; some patients had more than one event.
‡Lower limb arterial embolus (2); upper limb arterial thrombosis.
§Multivariate analysis including patient age and previous history of venous thrombosis.
¶Pericardial (2), urinary (2), postoperative and obstetric.
Multivariate analysis including patient age and previous history of arterial thrombosis.
#MPL-mutant group comprises 1 patient with MPL S505N and 1 patient with MPL W515K.
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an MPD28 and 9 children with ET,29 both of which failed to identify
MPL mutations outside exon 10. Our results demonstrate that
mutations outside MPL exon 10 are not a common cause of
V617F ET but do not exclude the existence of such mutations in a
small minority of patients. Changes elsewhere in MPL have
recently been reported, although it is not yet clear if they are
acquired mutations or inherited polymorphisms.30 Previous studies
have reported the W515L and W515K allele in IMF17,19 but only the
W515L allele in ET.17 Here we demonstrate the presence of the
W515K allele in patients with ET and also report 2 different
mutations capable of generating a W515K substitution. We also
report 2 patients with ET in whom an MPL S505N allele, previ-
ously reported as an inherited mutation,23,31 was detected in
granulocytes but was absent from buccal cells. Moreover in one of
the patients the mutation was only present in a minority of
erythroid colonies, and the other patient had a normal platelet count
over several years prior to presentation with ET, making somatic
mosaicism unlikely. Taken together, these findings strongly suggest
that the MPL S505N allele can occur as both an inherited and
acquired mutation. Mutations in the KIT gene have been reported in
patients with both sporadic and familial mast cell proliferations.
However the alleles involved are different, with inherited muta-
tions not seen in acquired disease and vice versa.32-41 We believe
this is the first example of a single allele being associated with both
acquired and inherited forms of an MPD.
In IMF our results demonstrate the presence of MPL mutations
in 7% of all patients and 15% of JAK2 V617F patients. These data
are similar to previous reports describing a prevalence of 5.5% or
8.5% in all patients17,19 and 9% in JAK2 V617F patients.16 In ET
the prevalence of MPL mutations was similar in our retrospective
and prospective cohorts. In our retrospective group of patients we
found the prevalence of MPL mutations to be 3.4% overall and
6.4% in JAK2 V617F patients. In the prospective PT-1 cohort, the
prevalence was 4.1% overall and 8.5% in JAK2 V617F patients.
These results are somewhat higher than the 1.3% overall preva-
lence previously reported,17 but are in keeping with data presented
in abstract form.42
Mutant allele burden was measured in the PT-1 cohort using
whole blood obtained at trial entry. ET patients with the W515K
allele had significantly higher allele burdens than those with the
W515L allele. This result is reminiscent of the observation that
most PV patients with a JAK2 V617F mutation have homozy-
gous erythroid colonies,27 whereas such clones are rarer in
patients with a JAK2 exon 12 mutation.6 JAK2 exon 12
mutations appear to signal more strongly than V617F mutations6
but it is not clear whether the difference between the W515L and
W515K mutations reflects quantitative or qualitative alterations
in signaling. Interestingly a peripheral blood allele burden of
more than 50% was found in 0 of 24 ET patients with the W515L
allele, but in 3 of 5 IMF patients. An allele burden of more than
50% implies the existence of one or more additional events
giving rise to homozygous or hemizygous mutant clones. Our
results would therefore be consistent with the concept that
patients labeled as having IMF may be presenting in an
accelerated phase of a previously undiagnosed MPD.43 Patients
with a longer disease duration, or in whom additional mutations
may have increased genomic instability would be expected to
have a greater probability of undergoing a second event.
The development of allele-specific PCR assays for each MPL
mutation allowed analysis of samples from the PT1 cohort together
with an assessment of the clinical and laboratory features associ-
ated with MPL mutations. This large cohort includes ET patients in
all risk categories, with centralized review of endpoints, comprehen-
sive follow-up, and the participation of a large number of second-
ary and tertiary centers. As such, these results are likely to be of
general relevance to ET patients with MPL mutations. Compared
with JAK2 V167F patients, those carrying an MPL mutation
exhibited lower hemoglobin levels and higher platelet counts at
diagnosis, higher serum erythropoietin levels and reduced bone
marrow erythroid and overall cellularity. Moreover it was possible
to grow thrombopoietin-independent megakaryocyte colonies but
not erythropoietin-independent erythroid colonies from ET patients
with an MPL mutation, an observation consistent with previous
data from patients with IMF.25,26 Taken together, these features
suggest that patients with MPL mutations have a lower drive
toward erythroid differentiation, accompanied by a more isolated
thrombocytosis. There were no consistent differences in other
histologic features including megakaryocyte morphology and reti-
culin grade. Compared with JAK2 V617F patients, those carrying
an MPL mutation were older at diagnosis with reduced bone
marrow cellularity that remained significant when patient age was
taken into account. However, it was not possible to identify other
clinical, histologic, or additional laboratory features that allowed
the MPL-mutant subgroup to be distinguished from the remaining
JAK2 V617F patients. Furthermore, MPL-mutant patients did not
exhibit altered rates of thrombosis, major hemorrhage, transforma-
tion, or death compared with V617F or V617F patients.
In this paper, we describe 44 patients with MPL mutations,
more than doubling the number thus-far reported in peer-reviewed
journals. Within the PT-1 cohort, however, the number of clinical
events in each category was small and statistical analyses were
associated with large confidence intervals. Our data should there-
fore be interpreted acknowledging the possibility of false negative
results. Our analysis also included a large number of hypothesis
tests, and to minimize the risk of false positive results, we applied a
threshold of P less than or equal to .01 for statistical significance.
Figure 2. Biologic aspects of MPL W515L and MPL W515K mutations. (A) Whole
blood mutant allele quantitation at trial entry showing significant difference in mean
mutant allele burden for MPL W515L (mean mutant allele burden 17%  11%,) and
MPL W515K (mean mutant allele burden 66%  26%, P  .001). (B) Genotyping of
single erythroid colonies from 5 ET patients, 4 with MPL W515L and 1 with MPL
S505N; a single homozygous colony was identified in patient 3.
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Known mutations in MPL and JAK2 account for 57% of the
PT-1 patients presented here. Comparisons between this group and
the remaining 43% who lack an identified mutation did not reveal
any significant differences in the prevalence of splenomegaly,
abnormal cytogenetics, myelofibrotic transformation, or acute
myeloid leukemia. There were also no differences between the
mutation-negative and mutation-positive groups in histologic fea-
tures other than cellularity. Taken together these findings suggest
that mutation-negative patients do have a myeloproliferative disor-
der, the molecular basis for which remains obscure.
Combining our retrospective and prospective cohorts, we
identified MPL mutations in 36 patients with ET, only one of whom
carried a JAK2 V617F mutation. This is in marked contrast to the
only previous report in which 2 of 4 ET patients with an MPL
mutation carried a JAK2 V617F mutation,17 and suggests that the
frequency of such double positive patients is much less than
previously thought. We also identified MPL mutations in 8 IMF
patients, none of whom harbored a JAK2 V617F mutation. This
observation is not significantly different from previous studies in
which 4 of 1617 or 4 of 1819 patients with an MPL mutation carried
a JAK2 V617F mutation. If the prevalence of patients with both
MPL and JAK2 mutations does prove to be higher in IMF
compared with ET, this would be consistent with the concept that
IMF represents patients presenting in an accelerated phase of a
preexisting MPD.43
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